Individualising Tyrosine Kinase Inhibitor Therapy in CML to Facilitate Successful Treatment Free Remission

该项目将确定慢性髓细胞白血病(CML)患者的最佳治疗方案，根据每个患者的独特生物学特征，为每个患者匹配最合适的药物，从而最大限度地增加治愈的机会。此外，该项目将开发新的高灵敏度检测残留疾病的存在，即使目前的技术无法检测到。这将使具有治疗意图的关键的、及时的治疗改变成为可能。

This project will determine the optimal therapy for patients with chronic myeloid leukaemia (CML), matching the most appropriate drug to the individual patient, based on each patient's unique biology, thereby maximising the chance of cure. Furthermore, this project will develop novel highly sensitive tests for the presence of residual disease, even if undetectable by current techniques. This will enable crucial, timely treatment changes to be made with curative intent.